Patent · US Active

CD33 binding agents

US9079958B2 · kind B2 · utility

5Cited by

1References

31Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Renate Konopitzky · Bad Vöslau, AT
Eric Borges · Weitensfeld im Gurktal, AT
Paul Adam · Wien, AT
Karl-Heinz Heider · Stockerau, AT

Key dates

Filing date	Sep 27, 2011
Grant date	Jul 14, 2015
Priority date	—
Expiry date	Dec 4, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.